Authorities File Bribery Charges Against Senior Officials Of Pharma Company And SFDA
This article was originally published in PharmAsia News
Executive SummaryChen Haifeng, head of China's State FDA's Center for Drug Evaluation and Gu Lijun, pharma company general manager, were taken to court for alleged bribery and corruption to the tune of RMB 1.3 million between 2004-2007 for fast drug registration approvals
You may also be interested in...
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.